Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASSAD H MOUHAFFEL

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1760591010
CMS profile
555698
Location
WEST MONROE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,065.30

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,065.30 55

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASSAD H MOUHAFFEL

NPI 1760591010 · CMS profile ID 555698

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

WEST MONROE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760591010?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASSAD H MOUHAFFEL, NPI 1760591010, CMS profile ID 555698. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760591010?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ASSAD H MOUHAFFEL, NPI 1760591010, CMS profile ID 555698. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760591010?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ASSAD H MOUHAFFEL, NPI 1760591010, CMS profile ID 555698, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1760591010?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $1,065.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $16.3802/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726034367 CMS
AstraZeneca Pharmaceuticals LP $11.1302/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736452419 CMS
Boston Scientific Corporation $28.0201/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725328139 CMS
E.R. Squibb & Sons, L.L.C. $12.5901/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727841651 CMS
Novartis Pharmaceuticals Corporation $17.7901/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726034365 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,094.36 72
PY2020 $1,065.30 55
PY2021 $1,271.74 88
PY2022 $1,044.68 57
PY2023 $1,132.93 41
PY2024 $1,714.74 39
PY2025 $644.73 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $583,089.43 47
PY2024 Principal investigator $402,026.89 15
PY2023 Principal investigator $92,743.24 5
PY2022 Principal investigator $61,183.00 92
PY2021 Principal investigator $57,104.98 154
PY2020 Recipient $5,000.00 1
PY2020 Principal investigator $104,253.76 48
PY2019 Recipient $5,000.00 1
PY2019 Principal investigator $130,184.64 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,454.30 12/16/2025 Non-covered Recipient Entity
MONROE RESEARCH LLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190314017
Principal investigator 1 Janssen Research & Development, LLC $14,868.00 12/15/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224935
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,088.34 12/05/2025 Non-covered Recipient Entity
MONROE RESEARCH LLC
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190314015
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,342.72 12/04/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Finality Study #22618 No dispute reported 06/30/2026 1225420185
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Monroe Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735157
Principal investigator 1 Janssen Research & Development, LLC $8,616.00 11/21/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224869
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,220.80 11/06/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Finality Study #22618 No dispute reported 06/30/2026 1225420105
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $736.00 11/06/2025 Non-covered Recipient Entity
Monroe Biomedical Research
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420257
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Monroe Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735155
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Monroe Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735159
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Monroe Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735161
Principal investigator 1 Novartis Pharmaceuticals Corporation $79,601.89 10/27/2025 Non-covered Recipient Entity
MONROE RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190308068
Principal investigator 1 Janssen Research & Development, LLC $7,308.00 10/22/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224961
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $405.76 10/08/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Finality Study #22618 No dispute reported 06/30/2026 1225419923
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,638.40 10/08/2025 Non-covered Recipient Entity
Monroe Biomedical Research
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420259
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Monroe Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735147
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 10/01/2025 Non-covered Recipient Entity
Monroe Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735149
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/01/2025 Non-covered Recipient Entity
Monroe Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735151
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
Monroe Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220735153
Principal investigator 1 Janssen Research & Development, LLC $7,446.00 09/19/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224902
Principal investigator 1 AstraZeneca Pharmaceuticals LP $94,947.55 09/10/2025 Non-covered Recipient Entity
MONROE RESEARCH, LLC
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185541726
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,685.76 09/08/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Finality Study #22618 No dispute reported 06/30/2026 1225419929
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,572.16 09/08/2025 Non-covered Recipient Entity
Monroe Biomedical Research
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420251
Principal investigator 1 Janssen Research & Development, LLC $4,746.00 08/25/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224878
Principal investigator 1 Janssen Research & Development, LLC $620.00 08/22/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224927
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,938.56 08/04/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Finality Study #22618 No dispute reported 06/30/2026 1225420047
Principal investigator 1 Amgen Inc. $10,966.10 07/31/2025 Non-covered Recipient Entity
MONROE RESEARCH LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246644815
Principal investigator 1 Janssen Research & Development, LLC $5,674.00 07/23/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224912
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,405.76 07/09/2025 Non-covered Recipient Entity
Monroe Biomedical Research
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420261
Principal investigator 1 Amgen Inc. $2,226.00 06/26/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF AMERICA LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246640379
Principal investigator 1 Janssen Research & Development, LLC $775.00 06/26/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224887
Principal investigator 1 Janssen Research & Development, LLC $5,670.00 06/25/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224896
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,066.40 06/23/2025 Non-covered Recipient Entity
MONROE RESEARCH, LLC
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185541728
Principal investigator 1 Janssen Research & Development, LLC $22,382.00 06/20/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224943
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,292.80 06/02/2025 Non-covered Recipient Entity
Monroe Biomedical Research
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420265
Principal investigator 1 Janssen Research & Development, LLC $11,840.00 05/16/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224951
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,927.36 05/06/2025 Non-covered Recipient Entity
Monroe Biomedical Research
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420253
Principal investigator 1 Amgen Inc. $89,747.00 04/23/2025 Non-covered Recipient Entity
MONROE RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246644822
Principal investigator 1 Janssen Research & Development, LLC $4,108.00 04/23/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224919
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,424.00 04/22/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Finality Study #22618 No dispute reported 06/30/2026 1225420073
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,091.52 04/07/2025 Non-covered Recipient Entity
Monroe Biomedical Research
Confirmation Study #22563 No dispute reported 06/30/2026 1225420255
Principal investigator 1 Janssen Research & Development, LLC $4,508.00 03/17/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224969
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,424.00 02/25/2025 Non-covered Recipient Entity
Monroe Biomedical Research
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420263
Principal investigator 1 Janssen Research & Development, LLC $3,454.00 02/24/2025 Non-covered Recipient Entity
Monroe Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224862
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,912.38 01/24/2025 Non-covered Recipient Entity
MONROE RESEARCH LLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190308070
Principal investigator 1 Amgen Inc. $58,972.18 01/13/2025 Non-covered Recipient Entity
MONROE RESEARCH LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246644818
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $34,267.26 01/01/2025 Non-covered Recipient Entity
MONROE RESEARCH LLC
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214125296